Otello Corporation ASA OTEC
OSL · Norway · Technology Services
NOK 18.74-0.14 (-0.74%)
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The Swiss drugmaker will pay $575 million upfront to license ABO2203, with up to $7.2 billion more tied to milestones
AGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.
Novartis (NYSE:NVS) has entered into a licensing agreement with Chinese biotechnology company Abogen covering an experimental RNA-based therapy and other potential treatments developed using Abogen’s technology platform. Under the agreement, Abogen will receive an upfront payment of $575 million and could receive an additional $7.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.